BRAF and thyroid gland carcinoma: Some identified genetic alterations in patients with thyroid carcinomas are changes in tyrosine kinase domain of RET gene in 15 – 33 %, RAS mutations detected in 10% and B-RAF mutations in 40-60% of cases.